Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An ISA to Master Protocol ARGX-999-2-MG-2000 for an Exploratory, Phase 2a, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV as Add-On Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

NCT07284420 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT07284420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07284420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An ISA to Master Protocol ARGX-999-2-MG-2000 for an Exploratory, Phase 2a, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV as Add-On Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Lead sponsor
argenx
Phase
Phase 2
Overall status
Recruiting
Start date
December 19, 2025
Completion date
March 7, 2028
Enrollment
70 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

achr-ab seropositive generalized myasthenia gravis, generalized myasthenia gravis, generalized myasthenia gravis (gmg), gmg, mg, myasthenia gravis